ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ) today announced the results from the Substrate versus Trigger Ablation for Reduction of Atrial Fibrillation (STAR-AF) trial. The findings were presented today during a late-breaking clinical trials session at Heart Rhythm 2009, the annual Heart Rhythm Society’s Scientific Sessions in Boston.
